Patrik Renblad joined SynAct Pharma as Vice President Finance in
"I am proud and honored of the appointment as CFO of SynAct Pharma. It is a great company with fantastic opportunities ahead. I am committed to growing the shareholder value and my first and top priority for 2022 will be to take the company through the IPO process towards a listing on Nasdaq Main Market", said Patrik Renblad, CFO of SynAct.
Henrik Stage, who has been CFO since 2016, remains affiliated to SynAct as a Special Advisor to the CEO until the Company has been approved for and initiated trading on Nasdaq Main Market in
"I am confident that we have found a strong CFO who is devoted to SynAct. Patrik fits very well in the organization and will bring value to the company and our shareholders. I would also like express my sincere gratitude for Henrik Stage and his contribution to SynAct. Henrik was instrumental in taking the Company public in 2016, has led several financing rounds, and helped bring SynAct to where it is today", said Jeppe Øvlesen, CEO.
The information was submitted, through the agency of the contact person below, for publication on
For further information about SynAct
Jeppe Øvlesen
CEO,
Phone: +45 28 44 75 67
Mail: joo@synactpharma.com
CSO,
Phone: +45 40 15 66 69
Mail: tj@synactpharma.com
About SynAct Pharma AB
https://news.cision.com/synact/r/synact-pharma-appoints-patrik-renblad-as-cfo,c3482348
https://mb.cision.com/Main/14427/3482348/1517658.pdf
https://news.cision.com/synact/i/patrik-renblad-cfo,c2997872
(c) 2022 Cision. All rights reserved., source